Icariin has been found to improve the imbalance between plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (t-PA) activities, thereby reducing platelet activation in hypercholesterolemia in a rabbit model of atherosclerosis (Zhang et al., 2013). This evidence concerns the gene PLAT and Hypercholesterolemia.